Duloxetine: a dual reuptake inhibitor
- PMID: 15522980
- DOI: 10.1345/aph.1E084
Duloxetine: a dual reuptake inhibitor
Abstract
Objective: To review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of duloxetine for the treatment of major depressive disorder (MDD).
Data sources: Searches using MEDLINE and PsycINFO were conducted (1966 to November 2003).
Study selection and data extraction: All duloxetine MDD information gathered was considered. Articles containing comprehensive information regarding duloxetine use for MDD were evaluated.
Data synthesis: Duloxetine is a serotonin-norepinephrine reuptake inhibitor being considered for treatment of MDD and stress urinary incontinence. While approved dosing ranges have not yet been determined, studies support the efficacy and safety of 40-60 mg twice daily for the treatment of acute MDD. Adverse effects have been of mild to moderate severity and are considered to be transient. Cardiovascular effects (increased heart rate or blood pressure), while present, do not appear to be clinically significant. Overall, duloxetine appears to be well tolerated.
Conclusions: Duloxetine is a safe and effective antidepressant. Approval of this agent provides another treatment option for the management of MDD.
Similar articles
-
An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.Drug Saf. 2007;30(5):437-55. doi: 10.2165/00002018-200730050-00007. Drug Saf. 2007. PMID: 17472422
-
Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor.Am J Health Syst Pharm. 2005 Dec 1;62(23):2481-90. doi: 10.2146/ajhp050006. Am J Health Syst Pharm. 2005. PMID: 16303903 Review.
-
Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder.J Clin Psychiatry. 2003;64 Suppl 13:30-7. J Clin Psychiatry. 2003. PMID: 14552654 Review.
-
The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression.Curr Pharm Des. 2005;11(12):1475-93. doi: 10.2174/1381612053764805. Curr Pharm Des. 2005. PMID: 15892657 Review.
-
Duloxetine: a new approach for treating stress urinary incontinence.Int J Gynaecol Obstet. 2004 Jul;86 Suppl 1:S53-62. doi: 10.1016/j.ijgo.2004.05.009. Int J Gynaecol Obstet. 2004. PMID: 15302567 Review.
Cited by
-
Possible Role of Cyclic AMP Response Element Binding/Brain-Derived Neurotrophic Factor Signaling Pathway in Mediating the Pharmacological Effects of Duloxetine against Methamphetamine Use-Induced Cognitive Impairment and Withdrawal-Induced Anxiety and Depression in Rats.Adv Biomed Res. 2019 Feb 21;8:11. doi: 10.4103/abr.abr_34_18. eCollection 2019. Adv Biomed Res. 2019. PMID: 30993081 Free PMC article.
-
Alpha2-adrenoceptor blockade potentiates the effect of duloxetine on sneeze induced urethral continence reflex in rats.J Urol. 2010 Aug;184(2):762-8. doi: 10.1016/j.juro.2010.03.106. Epub 2010 Jun 19. J Urol. 2010. PMID: 20639053 Free PMC article.
-
Serotonin and noradrenaline reuptake inhibitors improve micturition control in mice.PLoS One. 2015 Mar 26;10(3):e0121883. doi: 10.1371/journal.pone.0121883. eCollection 2015. PLoS One. 2015. PMID: 25812116 Free PMC article.
-
Mechanisms, Predictors, and Challenges in Assessing and Managing Painful Chemotherapy-Induced Peripheral Neuropathy.Semin Oncol Nurs. 2019 Jun;35(3):253-260. doi: 10.1016/j.soncn.2019.04.006. Epub 2019 Apr 30. Semin Oncol Nurs. 2019. PMID: 31053396 Free PMC article. Review.
-
Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials.Prim Care Companion J Clin Psychiatry. 2010;12(3):PCC.09r00845. doi: 10.4088/PCC.09r00845blu. Prim Care Companion J Clin Psychiatry. 2010. PMID: 20944767 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
